BLCOBausch + Lomb Corp.
BLCO
Bausch + Lomb Corp.526
Mkt Cap
$5.84BVolume
299,848.0052W High
$18.9252W Low
$10.45PE Ratio
-16.18BLCO Fundamentals
Price
$16.62Prev Close
$16.49Open
$16.2750D MA
$16.88Beta
1.16Avg. Volume
449,668.63EPS (Annual)
-$1.02P/B
0.91Rev/Employee
$392,384.61$10,971.61
Tudor Investment Corp ET AL Makes New Investment in Bausch + Lomb Corporation $BLCO
Tudor Investment Corp ET AL purchased a new position in Bausch + Lomb Corporation (NYSE:BLCO - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The...
MarketBeat·1d ago
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+ Dual-Port Vitrectomy Cutter and Adaptive Fluidics Advanced Update
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has...
Business Wire·5d ago
Bausch + Lomb Launches Preloaded enVista Envy Full Range of Vision Intraocular Lenses in Europe
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European commercial availability of the...
Business Wire·6d ago
Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of new scientific data and...
Business Wire·7d ago
Bausch + Lomb Corporation (NYSE:BLCO) Receives Average Rating of "Hold" from Analysts
Shares of Bausch + Lomb Corporation (NYSE:BLCO - Get Free Report) have been given an average recommendation of "Hold" by the fifteen ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, ten have given a hold reco...
MarketBeat·14d ago
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday...
Business Wire·14d ago
Tudor Investment Corp ET AL Takes $2.25 Million Position in Bausch + Lomb Corporation $BLCO
Tudor Investment Corp ET AL bought a new position in Bausch + Lomb Corporation (NYSE:BLCO - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 149,270 shares of the company's stock, valued a...
MarketBeat·15d ago
Short Interest in Bausch + Lomb Corporation (NYSE:BLCO) Increases By 50.7%
Bausch + Lomb Corporation (NYSE:BLCO - Get Free Report) saw a significant increase in short interest during the month of March. As of March 13th, there was short interest totaling 4,006,617 shares, an increase of 50.7% from the February 26th total of 2,659,462 shares. Approximately 1.1% of the...
MarketBeat·16d ago
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story
Key PointsAlfonso Eduardo acquired 4,300 common shares on March 2, 2026, at around $17.90 per share, for a total transaction value of ~$77,000...
Nasdaq News: Markets·20d ago
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS System for Treatment of Glaucoma
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced positive 24-month results from the pivotal U.S...
Business Wire·21d ago
<
1
2
...
>